Sewa S. Legha
#165,953
Most Influential Person Now
Sewa S. Legha's AcademicInfluence.com Rankings
Sewa S. Leghamedical Degrees
Medical
#3418
World Rank
#3886
Historical Rank
Cardiology
#363
World Rank
#374
Historical Rank
Pharmacology
#428
World Rank
#481
Historical Rank

Sewa S. Leghaphilosophy Degrees
Philosophy
#9771
World Rank
#13377
Historical Rank
Logic
#6727
World Rank
#8272
Historical Rank

Download Badge
Medical Philosophy
Why Is Sewa S. Legha Influential?
(Suggest an Edit or Addition)Sewa S. Legha's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. (1982) (744)
- Tamoxifen in the treatment of breast cancer. (1988) (621)
- Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. (2002) (358)
- Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. (1997) (299)
- Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. (1998) (284)
- Prognostic factors in metastatic breast cancer treated with combination chemotherapy. (1979) (281)
- A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. (1984) (237)
- Treatment of uveal melanoma metastatic to the liver. A review of the M. D. Anderson cancer center experience and prognostic factors (1995) (236)
- Prognostic factors for survival of patients treated systemically for disseminated melanoma. (1998) (219)
- Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. (1998) (199)
- Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. (1996) (174)
- A prospective evaluation of a triple‐drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma (1989) (169)
- A phase II trial of taxol in metastatic melanoma (1990) (168)
- Multivariate analysis of prognostic factors in metastatic breast cancer. (1983) (154)
- Pleural mesothelioma: clinical features and therapeutic implications. (1977) (152)
- Systemic treatments for advanced cutaneous melanoma. (1995) (148)
- Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. (1996) (131)
- Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. (1987) (129)
- Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later (2001) (127)
- Doxorubicin‐induced congestive heart failure in adults (1985) (116)
- CLINICAL AND PHARMACOLOGIC INVESTIGATION OF THE EFFECTS OF α‐TOCOPHEROL ON ADRIAMYCIN CARDIOTOXICITY * (1982) (114)
- Uveal melanoma: natural history and treatment options for metastatic disease. (1999) (114)
- Chemotherapy for metastatic merkel cell carcinoma. Review of the M. D. Anderson hospital's experience (1988) (113)
- Role of computed tomography in the staging of patients with local-regional metastases of melanoma. (1995) (111)
- Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. (2006) (106)
- Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults. (1982) (104)
- Vincristine Neurotoxicity (1986) (102)
- Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. (1995) (100)
- Hormonal therapy of breast cancer: new approaches and concepts. (1978) (99)
- Pulmonary toxicity of mitomycin (1980) (96)
- Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. (1996) (94)
- Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. (1995) (93)
- Complete remissions in metastatic breast cancer treated with combination drug therapy. (1979) (93)
- 4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia. (1980) (92)
- Hexamethylmelamine. An evaluation of its role in the therapy of cancer (1976) (91)
- Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer (1982) (89)
- Interferons in the treatment of malignant melanoma. A review of recent trials (1986) (87)
- Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. (1993) (84)
- Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative. (1978) (80)
- High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity. (1985) (76)
- Antiestrogens in the treatment of breast cancer. (1976) (71)
- Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. (1997) (71)
- Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local‐regional metastases (1998) (71)
- Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules . (1987) (68)
- Phase I study of taxol using a 5-day intermittent schedule. (1986) (67)
- Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. (1990) (67)
- Evaluation of interleukin‐2 administered by continuous infusion in patients with metastatic melanoma (1996) (67)
- Management of breast cancer patients failing adjuvant chemotherapy with adriamycin‐containing regimens (1981) (66)
- Adjuvant chemotherapy for advanced nasopharyngeal carcinoma (1987) (63)
- Tamoxifen‐induced hypercalcemia in breast cancer (1981) (60)
- Phase I clinical investigation of homoharringtonine. (1984) (58)
- Therapeutic approaches in malignant mesothelioma. (1977) (55)
- Adriamycin and mitomycin C: possible synergistic cardiotoxicity. (1978) (53)
- Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. (1999) (49)
- Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. (1993) (47)
- High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. (1987) (45)
- The role of interferon alfa in the treatment of metastatic melanoma. (1997) (43)
- Nafoxidine–‐an antiestrogen for the treatment of breast cancer (1976) (42)
- Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). (1983) (41)
- Phase I trial of subcutaneous recombinant human interleukin‐2 in patients with metastatic melanoma (2002) (40)
- Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen. (1990) (39)
- Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. (1998) (38)
- Acute rhabdomyolysis after concurrent administration of interleukin‐2, interferon‐alfa, and chemotherapy for metastatic melanoma (1995) (37)
- Chemotherapy for metastatic carcinoid tumors: experiences with 32 patients and a review of the literature. (1977) (36)
- Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. (1996) (36)
- Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans. (1987) (35)
- Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. (1979) (35)
- Current therapy for malignant melanoma. (1989) (35)
- Cytotoxic chemotherapy in adrenal cortical carcinoma. (1980) (34)
- A randomized phase III trial of biochemotherapy versus interferon-&agr;-2b for adjuvant therapy in patients at high risk for melanoma recurrence (2009) (34)
- Evaluation of silicone elastomer catheters for long-term intravenous chemotherapy. (1985) (34)
- Phase II study of thalidomide in patients with metastatic melanoma (2004) (32)
- Neurologic and cardiac rhythm abnormalities associated with 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) therapy. (1979) (30)
- Initial experience with AMSA as single agent treatment against malignant lymphoproliferative disorders. (1981) (30)
- Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. (1998) (30)
- Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. (1997) (28)
- Chemoimmunotherapy for meningeal melanocytoma of the thoracic spinal cord. Report of a case. (1979) (28)
- Adjuvant chemotherapy in lung cancer. Review and prospects (1977) (25)
- Study of Tumor-Infiltrating Lymphocytes for Adoptive Therapy of Renal Cell Carcinoma (RCC) and Metastatic Melanoma: Sequential Proliferation of Cytotoxic Natural Killer and Noncytotoxic T Cells in RCC (1991) (25)
- Phase I study of spirogermanium given daily. (1983) (25)
- Phase II study of recombinant alpha-interferon in malignant melanoma. (1990) (25)
- Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma. (1994) (24)
- Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. (1997) (23)
- Phase I clinical investigation of benzisoquinolinedione. (1987) (23)
- Neocarzinostatin (NSC 157365) a new cancerostatic compound. (1976) (23)
- Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas. (1986) (23)
- Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. (1979) (22)
- Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy (1980) (22)
- Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. (1979) (22)
- Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local‐regional recurrence of melanoma (1994) (21)
- Clinical pharmacology of trimetrexate (1987) (21)
- Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma. (1999) (19)
- Phase I trial of 1-(2′-deoxy-2′-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity (1989) (19)
- Spontaneous Rupture of Spleen in a Patient with Splenic Metastasis of Melanoma. A Case Report (1992) (19)
- Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen (1982) (18)
- Selective localization of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in B 16 melanoma. (1978) (18)
- Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy (1998) (18)
- Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma (1981) (17)
- Phase II trial of m-AMSA in hepatocellular carcinoma: a Southwest Oncology Group Study. (1982) (17)
- A Phase II study of “decrescendo” interleukin‐2 plus interferon‐α‐2a in patients with progressive metastatic melanoma after chemotherapy (2000) (16)
- Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC) in stage II or III breast cancer; 5-year results (1981) (16)
- Prediction of complete remission in patients with refractory acute leukemia treated with AMSA. (1984) (15)
- Letter: Antiestrogens in the treatment of cancer. (1976) (15)
- Phase II clinical evaluation of intravenous 4'-(9-acridinylamino)methanesulfon-m-anisidide in colorectal cancer. (1983) (15)
- Tamoxifen in breast cancer. (1978) (15)
- Treatment of brain metastases from melanoma. (2005) (14)
- Hormonal therapy with tamoxifen in male breast cancer. (1979) (14)
- Clinical pharmacokinetics of the new antitumor agent AMSA (1979) (14)
- Reduction of adriamycin cardiac toxicity using a prolonged continuous intravenous infusion (1981) (14)
- Phase II study of alpha-interferon and 13-cis-retinoic acid in metastatic melanoma (1993) (13)
- Acute cyclophosphamide hypersensitivity reaction: possible lack of cross-sensitivity to mechlorethamine and isophosphamide. (1978) (12)
- Intraarterial infusion chemotherapy in regionally advanced malignant melanoma (1990) (12)
- Hormone receptors in breast cancer and response to chemotherapy. (1979) (12)
- Ventricular fibrillation following AMSA. Uncomplicated retreatment following correction of hypokalemia (1983) (11)
- Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer. (1983) (11)
- Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma. (1980) (11)
- High-dose AMSA and bone marrow rescue in patients with solid tumors. (1982) (11)
- Phase I clinical trial and pharmacokinetic evaluation of 4′-0-tetrahydropyranyladriamycin (THP-adriamycin) (1989) (10)
- Clinical studies with rubidazone. (1979) (10)
- Continuous-Infusion Adriamycin (1986) (10)
- Phase I trial of caracemide using bolus and infusion schedules. (1987) (10)
- Peptichemio versus melphalan (L‐PAM) in advanced breast cancer (1982) (10)
- Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine. (1980) (9)
- Pilot study of intra-arterial cisplatin and intravenous vinblastine and dacarbazine in patients with melanoma in-transit metastases. (1999) (9)
- Systemic therapy of metastatic breast cancer: a review of the current trends. (1982) (9)
- The Phase I Study: General Objectives, Methods, and Evaluation (1987) (9)
- Interlenkin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M. D. Anderson Cancer Center (1989) (9)
- Adriamycin Cardiac Toxicity — An Assessment of Approaches to Cardiac Monitoring and Cardioprotection (1988) (8)
- A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma (2006) (8)
- Augmentation of adriamycin's therapeutic index by prolonged continuous i.v. infusion for advanced breast cancer (1979) (8)
- A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-α-2b (IFN) in patients (pts) with high risk for melanoma recurrence. (2006) (8)
- Efficacy of ondansetron against nausea and vomiting caused by dacarbazine‐containing chemotherapy (1992) (8)
- Clinical pharmacokinetics of ifosfamide in combination with N‐acetylcysteine (1992) (8)
- PHASE I TRIAL OF MURINE ANTI-GANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (Mab) 14G2A IN CANCER PATIENTS (1992) (8)
- Phase I study of hycanthone. (1978) (8)
- Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma. (1979) (8)
- Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. (1994) (7)
- Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin. (1986) (7)
- Phase II Study of Recombinant α‐Interferon in Malignant Melanoma (1990) (7)
- Pulmonary toxicity associated with spirogermanium. (1984) (7)
- m‐AMSA in epithelial carcinoma of the ovary A Southwest Oncology Group study (1983) (6)
- A Phase I trial of weekly lomustine in patients with advanced cancer (1994) (6)
- Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer (1983) (6)
- Role of Adriamycin in Breast Cancer and Sarcomas (1982) (6)
- Mitotane failure in adrenocortical cancer: Where next? (1993) (6)
- AMSA: A new acridine derivative with activity against metastatic melanoma (1979) (6)
- Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma. (1993) (6)
- Detorubicin--an active anthracycline in untreated metastatic melanoma. (1985) (6)
- DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma (1998) (5)
- Phase II evaluation of AMSA in adult sarcomas. (1981) (5)
- Phase II study of spirogermanium in the treatment of metastatic breast cancer. (1984) (4)
- Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. (1991) (4)
- A review of mitomycin regimens in advanced breast cancer therapy. (1985) (4)
- Biochemotherapy using interleukin-2 + interferon alpha-2a (IFN) in combination with cisplatin (C), vinblastine (V) and DTIC (D) in patients with metastatic melanoma: 113 (1993) (4)
- Phase I studies of trimetrexate using single and weekly dose schedules (1991) (4)
- Hepatotoxicity of hycanthone in patients with metastatic breast cancer. (1980) (4)
- Zinostatin-related pulmonary toxicity. (1981) (4)
- Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio (1984) (4)
- Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy (1991) (3)
- Long-term clinical results of the combination of cisplatin (C), vinblastine (V), DTIC (D) and interferon-alfa (I) with or without tamoxifen (T) for metastatic melanoma. (2006) (3)
- Amsacrine (m-AMSA) in squamous cell carcinoma of the uterine cervix: a Southwest Oncology Group study. (1984) (3)
- Phase II trial of amsacrine in pancreatic carcinoma: a Southwest Oncology Group study. (1984) (3)
- Rubidazone in metastatic breast cancer. (1979) (3)
- Interleukin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M.D. Anderson Cancer Center. (1989) (3)
- Reutilization of adriamycin in previously treated patients (1981) (3)
- Therapy of advanced breast cancer. (1977) (3)
- Treating metastatic melanoma: further considerations. (2009) (2)
- 18 Preoperative chemotherapy with cisplatin, vinblastine and dacarbazine (CVD) in patients with local-regional recurrence of melanoma (AJCC stage-HI) (1995) (2)
- Doxorubicin toxicity. (1981) (2)
- Differences in nativity, age and gender may impact health behavior and perspectives among Asian Indians (2019) (2)
- Phase II trial of amsacrine in metastatic or locally recurrent squamous cell carcinoma from head and neck primaries: a Southwest Oncology Group study. (1984) (2)
- Evaluation of α-tocopherol against adriamycin cardiotoxicity in humans (1981) (2)
- AMSA toxicity in patients with abnormal liver function. (1981) (2)
- Reduction of adriamycin cardiotoxicity by continuous IV infusion: The effect of duration of infusion on cardiotoxicity (1982) (2)
- High-dose AMSA and autologous bone marrow transplantation in relapsed acute leukemia. (1982) (2)
- Phase II trial of tirapazamine (escalated dose) plus cisplatin in patients with advanced melanoma: 024 (1997) (1)
- Reduction of Adriamycin Cardiac Toxicity by Schedule Manipulation (1982) (1)
- Correction: Dosage of Thioguanine (1975) (1)
- MITOTANE FAILURE IN ADRENOCORTICAL CANCER : WHERE NEXT ? AUTHOR'S REPLY (1993) (1)
- m-AMSA and adenocarcinoma of the endometrium (2004) (1)
- Biochemotherapy studies in the treatment of advanced melanoma: 081 (1997) (1)
- Re: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. (1995) (1)
- m-AMSA: a new anticancer agent. (1980) (1)
- Malignant Melanoma: Biology, Diagnosis, and Management (2005) (1)
- m-AMSA and adenocarcinoma of the endometrium. A Southwest Oncology Group study. (1984) (1)
- Pre-treatment characteristics predictive of complete remission in patients with relapsed acute leukemia treated with AMSA (1982) (1)
- Peptichemio in treatment of advanced refractory breast cancer - A phase II study (1979) (1)
- Phase II study of PCNU in the treatment of head and neck carcinoma. (1984) (1)
- AMSA and peptichemio in the treatment of advanced metastatic breast cancer: A phase II study (1982) (1)
- Nitric oxide (NO), neopterin, and cytokine levels versus clinical response in stage III melanoma patients receiving concurrent biochemotherapy: 390 (1997) (0)
- Antiestrogens in the treatment of cancer. (Letter to the editor) (1976) (0)
- 18 Adjuvant biochemotherapy for patients with stage-III melanoma: a pilot study (2004) (0)
- Drug-associated cardiotoxicity. (1979) (0)
- Evaluation of Silicone Elastomer Catheters for Long-Term Intravenous Chemotherapy (1985) (0)
- A PHASE I-II evaluation of trioxifene mesylate in the treatment of advanced breast cancer (1981) (0)
- 600 Improved remission rate and duration of remission associated with hormone-adriamycin chemotherapy (1983) (0)
- Antlestrogens in the treatment of breast cancer (1976) (0)
- Books Received (1994) (0)
- 18 Results of biochemotherapy in the treatment of advanced melanoma,The M.D. Anderson Cancer Center Experience (1997) (0)
- Phase I evaluation of Hepatic arterial infusion of interferon alfa-2b in patients with liver cancer (1996) (0)
- Therapy of advanced melanoma, Philip Rumke MD (Ed.). S. Karger, Basel (1990), 230 pages. $132.00. (1991) (0)
- Treatment of brain metastases from melanoma. Author's reply (2005) (0)
- Basic Science of Cancer (2001) (0)
- 19 Potential of interleukin-2 in the future adjuvant therapy for high-risk melanoma (1999) (0)
- Role of chemotherapy in advanced melanoma (2007) (0)
- INV 19 Role of chemotherapy in advanced melanoma (2007) (0)
- Summary of trials involving high dose IL-2 in patients with advanced melanoma: 407 (1997) (0)
- Phase II study of AMSA alone and in combination with DTIC in patients with metastatic melanoma (1988) (0)
- Tamoxifen in breast cancer (1986) (0)
- Remission and survival data of metastatic breast cancer patients (PTS) achieving complete remission (CR) with combination chemoimmunotherapy (CI) (1978) (0)
- Advances in the Diagnosis and Treatment of Malignant Melanoma (1997) (0)
- What is the best new anti-melanoma therapy?: 153 (1997) (0)
- Novel Strategies for the Treatment of Melanoma (2007) (0)
- Cutaneous melanoma. (1992) (0)
- Impact of regional (ia) vs systemic (iv) therapy (rx) on survival of patients (pts) with liver metastasis (lm) from choroidal malignant melanoma (cmm): 378 (1993) (0)
- Emerging therapies for melanoma (2013) (0)
- United States Patent ( 19 ) Canetta et al . 54 METHOD FOR EFFECTING TUMIOR REGRESSION WITH A LOW DOSE (2017) (0)
- Evaluation of tamoxifen in chemotherapy resistant metastatic breast cancer (1978) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Sewa S. Legha?
Sewa S. Legha is affiliated with the following schools: